Skip to main content

Table 2 Meta- Analysis for CIMP-H prevalence across countries

From: Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer

Continent

Country

Mean CIMP-H prevalence

95% CI

Smoking %

Alcohol drinkers %

Obesity%

Africa

Tunisia

32%

23–42%

40.93%

20%

27%

Australia

Australia

20%

13–27%

14.8%

11.9%

29%

New Zealand

35%

26–45%

14.9%

12%

31%

Asia

China

24%

12–35%

25.2%

10.6%

6%

India

44%

37–51%

11.3%

22.3%

4%

Japan

26%

20–32%

22.5%

9.90%

4%

Taiwan

16%

12–20%

18%

NA

NA

South Korea

21%

11–31%

23.6

19.90%

7%

Kuwait

9%

5–16%

19.9%

3.10%

38%

Saudi Arabia

6%

3–10%

13.6%

NA

35%

Europe

Greece

10%

6–15%

43.7%

15%

25%

Italy

21%

14–28%

23.8%

13%

20%

Spain

24%

18–31%

29.4%

21%

24%

France

17%

15–19%

32.9%

14.90%

22%

Switzerland

9%

6–12%

25.8%

13.40%

20%

United Kingdom

12%

1–24%

22.4%

15.60%

28%

Netherlands

34%

21–48%

25.9%

13.90%

20%

Norway

19%

17–21%

20.2%

8.70%

23%

Sweden

13%

11–15%

18.9%

12.50%

21%

Denmark

38%

35–42%

19.1%

14.40%

20%

Germany

16%

12–20%

30.7%

13.40%

22%

Poland

25%

19–31%

28.2%

17.90%

23%

Czech Republic

50%

42–59%

34.4%

19.50%

26%

Ireland

43%

29–58%

24.4%

19.30%

25%

North America

United States

27%

23–31%

21.9%

14.40%

36%

South America

Brazil

25%

18–31%

14%

18.50%

22%

  1. CIMP-H CIMP-High, CI 95% Confidence Interval, % Prevalence as % using World Health Organization data, NA Not available